About us

HOMEAbout us

Our Mission

Contribute to the health of people everywhere through
the provision of specialized blood cells created by regenerative medicine technology.

We produce and supply the necessary amount of homogeneous and highly accurate “human blood cells” using regenerative medicine technology, which dramatically improves the efficiency of research on infectious diseases and the evaluation of efficacy and safety of pharmaceuticals and functional materials. We also sell evaluation kits and provide contracted evaluation services.

Company Profile

Name of company	MiCAN Technologies, Inc.
Address	・Head Office (Kyoto Research Institute)　Kyoto-University Katsura Venture Plaza, 1-36 Goryo-ohara, Nishikyo-ku, Kyoto 615-8245 Japan TEL: +81-75-381-3008 Google map ・Kobe manufacturing plant　BMA, 1-5-5 Minatojima Minamicho, Chuo-ku, Kobe, Hyogo 650-0047 Japan Google map ・European Development Office　BioLabs Heidelberg Nikola-Tesla-Strasse 1, 69124 Heidelberg Germany Google map
Representative	Kazuo Miyazaki, Chief Executive Officer
Established	July 2016
Capital	¥54,990,000
Business lineup	Provision (sales) of blood cell-like cells for research using regenerative medicine technologies Evaluation service for pharmaceutical development(contract service) using the above-stated blood cell-like cells Contract service of various tests using the above-stated blood cell-like cells based on alternative methods to animal testing

Our History

2015	Accepted in the Support System for Venture Companies Solving Unmet Medical Needs of the Ministry of Economy, Trade and Industry
2016 July	Foundation(Chuo-ku, Tokyo)
2016 November	Awarded a grand prize of GLOBIS Venture Challenge
2017 October	Development of red blood-like cells for research of infectious diseases (Mpv cells, first product) with Kyoto University and Nagasaki University, patent application
2017 December	Started development of myeloid cells for research of viruses (Mylc cells, second product)
2018 February	Established a research and development base at Kyoto-University Katsura Venture Plaza
2018 July	Started release of red blood-like cells (prototype product of Mpv cells)
2018 August	Patent application for myeloid cells for research of viruses (Mylc cells, second product) with Osaka University and Kumamoto University
2018 September	Transferred the Headquarters to Kyoto-University Katsura Venture Plaza
2018 November	Adopted for the Economic Gardening Support Grant supported by KyotoIndustrial Support Organization 21
2018 December	Certified as Management of Wisdom by the Kyoto Chamber of Commerce and Industry
2019 March	Expanded the Headquarters and Laboratory
2019 April	Signed a collaborative research agreement on the development of culture medium with Nissui Pharmaceutical Co., Ltd.
2019 July	Started release of myeloid cells for research of viruses (prototype product)
2019 August	Raised \127,000,000 by allocation of shares to third parties including Osaka University Venture Capital Co., Ltd. (series A)
2020 April	Started collaborative research on corona virus using Mylc cells with Osaka University
2020 June	elected in Support for Improvement Research, Technology Development Project for Measures to Control Viral Infections, by AMED
2022 March	Won the Grand Prix in the Collaboration Category of the 2nd Wisdom-1 Grand Prix sponsored by the Kyoto Chamber of Commerce and Industry.
2022 March	Awarded “Real Tech Venture of the Year 2022” in the Growth category
2022 August	Adopted for the “Go-Tech Project” (R&D Support Project for Growth-oriented Small and Medium Enterprises)
2023 April	MyrcMAT Kit (for research), a kit for evaluation of thermogenic substances using immortalized myeloid cells (Mylc), is now available for testing.
2023 August	Raised 200 million yen through third-party allotment to real-tech funds and others (Series B)
2023 September	Selected for NEDO’s Deep Tech Startup Support Project PCA Phase (Practical Application R&D (late stage))